STAR THERAPEUTICS PRESENTS INTERIM DATA FROM PHASE 1/2 MULTIDOSE STUDY OF VGA039 IN VON WILLEBRAND DISEASE, DEMONSTRATING SUBSTANTIAL BLEED REDUCTIONS IN ALL PATIENTS, AT ASH ANNUAL MEETING VGA039 is a once monthly, subcutaneously self-administered therapy for the...
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days – ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and...
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized...
Flosonics Medical Receives Vizient Innovative Technology Contract for FloPatch Wearable Doppler UltrasoundContract recognizes FloPatch’s unique potential to improve fluid management decisions and patient outcomes in sepsis care LOS ANGELES, CALIF., March 3, 2026 —...
Aetna Approves Coverage for Cleerly’s AI Cardiovascular Imaging Analysis Major Insurer Joins UnitedHealthcare, Cigna, and Humana in Covering Cleerly’s AI-QCT Technology as Industry Momentum Builds with 86+ Million Lives Now Covered January 6, 2026 (DENVER,...
Recent Comments